To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize manufacturing schedules and resources. In battling the COVID-19 pandemic, ...
Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...
Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the ...
Ivonescimab’s progression-free survival data bode well for an upcoming overall survival readout, according to Truist analysts ...
Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events ...
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...
Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.
Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must continue.
After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have landed new roles—at Eli Lilly, Pfizer, Iovance and more. The FDA’s loss, it ...
Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s ...
After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback